Table of Contents
ISRN Critical Care
Volume 2013 (2013), Article ID 219048, 6 pages
http://dx.doi.org/10.5402/2013/219048
Research Article

Predictors of Disseminated Intravascular Coagulation in Patients with Septic Shock

1Department of Medicine, Mayo Clinic, 200 First Street SW, Rochester, MN 55905, USA
2Multidisciplinary Epidemiology and Translational Research in Intensive Care (METRIC), Rochester, MN 55905, USA
3Division of Pulmonary and Critical Care Medicine, Mayo Clinic, Rochester, MN 55905, USA

Received 6 August 2013; Accepted 2 September 2013

Academic Editors: M. S. C. de Assuncao and N. Gibney

Copyright © 2013 Diana J. Kelm et al. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

Linked References

  1. M. S. Rangel-Frausto, D. Pittet, M. Costigan, T. Hwang, C. S. Davis, and R. P. Wenzel, “The natural history of the systemic inflammatory response syndrome (SIRS): a prospective study,” The Journal of the American Medical Association, vol. 273, no. 2, pp. 117–123, 1995. View at Google Scholar · View at Scopus
  2. M. Antonelli, M. Levy, P. J. D. Andrews et al., “Hemodynamic monitoring in shock and implications for management,” Intensive Care Medicine, vol. 33, no. 4, pp. 575–590, 2007. View at Publisher · View at Google Scholar · View at Scopus
  3. E. Rivers, B. Nguyen, S. Havstad et al., “Early goal-directed therapy in the treatment of severe sepsis and septic shock,” The New England Journal of Medicine, vol. 345, no. 19, pp. 1368–1377, 2001. View at Publisher · View at Google Scholar · View at Scopus
  4. J. Kramer, H. M. Otten, M. Levi, and H. T. Cate, “The association of disseminated intravascular coagulation with specific diseases,” Reanimation, vol. 11, no. 8, pp. 575–583, 2002. View at Publisher · View at Google Scholar · View at Scopus
  5. F. B. Taylor, C. H. Toh, W. K. Hoots, H. Wada, and M. Levi, “Towards definition, clinical and laboratory criteria, and a scoring system for disseminated intravascular coagulation: on behalf of the scientific subcommittee on disseminated intravascular coagulation (DIC) of the international society on thrombosis and haematostasis (ISTH),” Thrombosis and Haemostasis, vol. 86, no. 5, pp. 1327–1330, 2001. View at Google Scholar · View at Scopus
  6. C. Voves, W. A. Wuillemin, and S. Zeerleder, “International society on thrombosis and haemostasis score for overt disseminated intravascular coagulation predicts organ dysfunction and fatality in sepsis patients,” Blood Coagulation and Fibrinolysis, vol. 17, no. 6, pp. 445–451, 2006. View at Publisher · View at Google Scholar · View at Scopus
  7. S. Zeerleder, C. E. Hack, and W. A. Wuillemin, “Disseminated intravascular coagulation in sepsis,” Chest, vol. 128, no. 4, pp. 2864–2875, 2005. View at Publisher · View at Google Scholar · View at Scopus
  8. S. Gando, “Microvascular thrombosis and multiple organ dysfunction syndrome,” Critical Care Medicine, vol. 38, no. 2, pp. S35–S42, 2010. View at Publisher · View at Google Scholar · View at Scopus
  9. M. Plataki, K. Kashani, J. Cabello-Garza et al., “Predictors of acute kidney injury in septic shock patients: an observational cohort study,” Clinical Journal of the American Society of Nephrology, vol. 6, no. 7, pp. 1744–1751, 2011. View at Publisher · View at Google Scholar · View at Scopus
  10. “American college of chest physicians/society of critical care medicine consensus conference: definitions for sepsis and organ failure and guidelines for the use of innovative therapies in sepsis,” Critical Care Medicine, vol. 20, no. 6, pp. 864–874, 1992.
  11. A. Kumar, D. Roberts, K. E. Wood et al., “Duration of hypotension before initiation of effective antimicrobial therapy is the critical determinant of survival in human septic shock,” Critical Care Medicine, vol. 34, no. 6, pp. 1589–1596, 2006. View at Publisher · View at Google Scholar · View at Scopus
  12. D. P. Eisen, “Manifold beneficial effects of acetyl salicylic acid and nonsteroidal anti-inflammatory drugs on sepsis,” Intensive Care Medicine, vol. 38, no. 8, pp. 1249–1257, 2012. View at Publisher · View at Google Scholar · View at Scopus
  13. J. Winning, J. Reichel, Y. Eisenhut et al., “Anti-platelet drugs and outcome in severe infection: clinical impact and underlying mechanisms,” Platelets, vol. 20, no. 1, pp. 50–57, 2009. View at Publisher · View at Google Scholar · View at Scopus
  14. D. J. Kor, J. Erlich, M. N. Gong et al., “Association of prehospitalization aspirin therapy and acute lung injury: results of a multicenter international observational study of at-risk patients,” Critical Care Medicine, vol. 39, no. 11, pp. 2393–2400, 2011. View at Publisher · View at Google Scholar · View at Scopus
  15. M. Sedlacek, J. M. Gemery, A. L. Cheung, A. S. Bayer, and B. D. Remillard, “Aspirin treatment is associated with a significantly decreased risk of Staphylococcus aureus bacteremia in hemodialysis patients with tunneled catheters,” The American Journal of Kidney Diseases, vol. 49, no. 3, pp. 401–408, 2007. View at Publisher · View at Google Scholar · View at Scopus
  16. G. P. Otto, M. Sossdorf, J. Boettel et al., “Effects of low-dose acetylsalicylic acid and atherosclerotic vascular diseases on the outcome in patients with severe sepsis or septic shock,” Platelets, vol. 24, no. 6, pp. 480–485, 2013. View at Publisher · View at Google Scholar
  17. S. H. Slofstra, C. A. Spek, and H. T. Cate, “Disseminated intravascular coagulation,” Hematology Journal, vol. 4, no. 5, pp. 295–302, 2003. View at Publisher · View at Google Scholar · View at Scopus
  18. B. Østerud and J. O. Olsen, “Human platelets do not express tissue factor,” Thrombosis Research, vol. 132, no. 1, pp. 115–114, 2013. View at Publisher · View at Google Scholar
  19. L. K. Jennings, “Mechanisms of platelet activation: need for new strategies to protect against platelet-mediated atherothrombosis,” Thrombosis and Haemostasis, vol. 102, no. 2, pp. 248–257, 2009. View at Publisher · View at Google Scholar · View at Scopus
  20. M. Levi, C. H. Toh, J. Thachil, and H. G. Watson, “Guidelines for the diagnosis and management of disseminated intravascular coagulation,” The British Journal of Haematology, vol. 145, no. 1, pp. 24–33, 2009. View at Publisher · View at Google Scholar · View at Scopus
  21. R. P. Dellinger, M. M. Levy, A. Rhodes et al., “Surviving sepsis campaign,” Critical Care Medicine, vol. 41, no. 2, pp. 580–637, 2013. View at Publisher · View at Google Scholar
  22. C. T. Esmon, “The protein C anticoagulant pathway,” Arteriosclerosis and Thrombosis, vol. 12, no. 2, pp. 135–145, 1992. View at Google Scholar · View at Scopus
  23. M. W. J. Boehme, Y. Deng, U. Raeth et al., “Release of thrombomodulin from endothelial cells by concerted action of TNF-α and neutrophils: in vivo and in vitro studies,” Immunology, vol. 87, no. 1, pp. 134–140, 1996. View at Google Scholar · View at Scopus
  24. J. A. Lorente, L. J. Garcia-Frade, L. Landin et al., “Time course of hemostatic abnormalities in sepsis and its relation to outcome,” Chest, vol. 103, no. 5, pp. 1536–1542, 1993. View at Google Scholar · View at Scopus
  25. G. R. Bernard, J. Vincent, P. Laterre et al., “Efficacy and safety of recombinant human activated protein C for severe sepsis,” The New England Journal of Medicine, vol. 344, no. 10, pp. 699–709, 2001. View at Publisher · View at Google Scholar · View at Scopus
  26. A. J. Martí-Carvajal, I. Solà, D. Lathyris, and A. F. Cardona, “Human recombinant activated protein C for severe sepsis,” Cochrane Database of Systematic Reviews, vol. 12, Article ID CD004388, 2012. View at Google Scholar · View at Scopus
  27. J. L. Priziola, M. A. Smythe, and W. E. Dager, “Drug-induced thrombocytopenia in critically ill patients,” Critical Care Medicine, vol. 38, no. 6, pp. S145–S154, 2010. View at Publisher · View at Google Scholar · View at Scopus